Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Inv. presentation
|
|
Akero Therapeutics, Inc. (AKRO)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 08/11/2023 |
8-K
| Quarterly results |
| 05/15/2023 |
8-K
| Quarterly results |
| 08/04/2022 |
8-K
| Quarterly results |
| 05/06/2022 |
8-K
| Quarterly results |
| 11/12/2021 |
8-K
| Quarterly results |
| 08/13/2021 |
8-K
| Quarterly results |
| 11/12/2020 |
8-K
| Quarterly results|
Docs:
|
"Akero Therapeutics Reports THIRD Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif., November 12, 2020 -- Akero Therapeutics, Inc. , a cardio-metabolic non-alcoholic steatohepatitis company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today reported third quarter financial results for the period ending September 30, 2020. “On the heels of reporting strongly positive histological data from our FGF21 analog, efruxifermin , we executed a number of important objectives in the third quarter that position us for continued success,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. “In addition to raising more than $216 million to enable continued development of EFX, we received feedbac..." |
|
| 08/12/2020 |
8-K
| Quarterly results |
| 05/13/2020 |
8-K
| Quarterly results|
Docs:
|
"Akero Therapeutics Reports first Quarter 2020 Financial Results SOUTH SAN FRANCISCO, Calif., May 13, 2020 -- Akero Therapeutics, Inc. , a cardio-metabolic non-alcoholic steatohepatitis company developing pioneering medicines designed to restore metabolic balance and improve the overall health of NASH patients, today reported first quarter financial results for the period ending March 31, 2020. “During the first quarter of 2020 we reported results for the primary endpoint and several secondary efficacy endpoints in our ongoing Phase 2a clinical trial, the BALANCED study, and continued to make important progress toward advancing AKR-001 as a potential cornerstone treatment for NASH,” said Andrew Cheng, M.D., Ph.D., president and chief executive officer of Akero. “The reductions in liver fat ..." |
|
| 03/16/2020 |
8-K
| Quarterly results |
| 11/12/2019 |
8-K
| Quarterly results |
| 08/12/2019 |
8-K
| Quarterly results |
|
|